DV
Dividend Vision

GALT — Galectin Therapeutics Inc

Galectin Therapeutics Inc (GALT)

Total return is -71.3% over the past 23.9 years, 1314.8 points behind SPY at 1243.5%. Its deepest 1-year drawdown was 68.0%.

GALT is a single-stock equity holding in Galectin Therapeutics Inc, a biopharmaceutical company. As a concentrated stock position rather than a diversified fund, it carries no regular dividend distribution and therefore offers no yield profile typical of dividend-focused ETFs. This holding appeals primarily to investors seeking direct exposure to a specific biotech company's growth potential rather than income generation.

GALT key facts

Asset type
Stock
Asset class
Equity
Inception date
09/04/2002
Last close
$3.44
Market cap
$274,952,544
Average volume
388200.0
Beta
0.353
Payout ratio
0.0
Forward P/E
4.5434
EPS
$-0.41